NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis $17.04 -0.21 (-1.22%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$17.00▼$17.3050-Day Range$6.53▼$18.4752-Week Range$6.20▼$27.96Volume1,708 shsAverage Volume56,531 shsMarket Capitalization$22.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pieris Pharmaceuticals alerts: Email Address Pieris Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.74% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$92,310 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.40 out of 5 starsMedical Sector443rd out of 909 stocksPharmaceutical Preparations Industry203rd out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals.Read more about Pieris Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.74% of the float of Pieris Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently decreased by 51.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePieris Pharmaceuticals has received a 71.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Pieris Pharmaceuticals is -0.81. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,310.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.89% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pieris Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pieris Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees need to hear. It's shocking to me that more people aren't wise to this, as they are leaving money on the table from stocks they have a strong belief in. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.CLICK HERE TO RSVP About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More PIRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PIRS Stock News HeadlinesAugust 13, 2024 | insidertrades.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 SharesAugust 16, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of ShareholdersSeptember 7, 2024 | Unstoppable Prosperity (Ad)Here’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees need to hear. It's shocking to me that more people aren't wise to this, as they are leaving money on the table from stocks they have a strong belief in. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.August 16, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRSAugust 16, 2024 | bizjournals.comInside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firmAugust 16, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 15, 2024 | msn.comPIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q2 2024August 14, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersSeptember 7, 2024 | Unstoppable Prosperity (Ad)Here’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees need to hear. It's shocking to me that more people aren't wise to this, as they are leaving money on the table from stocks they have a strong belief in. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.August 13, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRSJuly 25, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of ShareholdersJuly 24, 2024 | prnewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.July 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersJuly 24, 2024 | investorplace.comWhy Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?July 24, 2024 | msn.comTraders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity FuturesJuly 24, 2024 | marketwatch.comPieris Pharma Shares Double on Buyout Offer From Palvella TherapeuticsJuly 24, 2024 | msn.comPieris Pharma surges on all-stock merger dealJuly 24, 2024 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger AgreementSee More Headlines Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today9/06/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees140Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-39.71% Pretax Margin-114.11% Return on Equity-101.29% Return on Assets-65.00% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$42.81 million Price / Sales0.53 Cash FlowN/A Price / Cash FlowN/A Book Value$21.66 per share Price / Book0.79Miscellaneous Outstanding Shares1,320,000Free Float1,203,000Market Cap$22.49 million OptionableOptionable Beta0.66 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Comp: $744.13kMr. Thomas Bures (Age 49)Senior VP, CFO & Treasurer Comp: $487.5kDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Comp: $463.91kMaria KelmanExecutive Director of Investor RelationsMr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project LeadershipMore ExecutivesKey CompetitorsFibroGenNASDAQ:FGENVistagen TherapeuticsNASDAQ:VTGNAnnovis BioNYSE:ANVSAlloVirNASDAQ:ALVRCoya TherapeuticsNASDAQ:COYAView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPSold 8,735,663 shares on 8/15/2024Ownership: 3.295%Adar1 Capital Management, LlcBought 3,000 shares on 8/12/2024Total: $47,640.00 ($15.88/share)Adar1 Capital Management, LlcBought 3,000 shares on 8/9/2024Total: $44,670.00 ($14.89/share)Renaissance Technologies LLCSold 1,418,117 shares on 8/9/2024Ownership: 0.869%Acadian Asset Management LLCSold 951,531 shares on 8/6/2024Ownership: 0.820%View All Insider TransactionsView All Institutional Transactions PIRS Stock Analysis - Frequently Asked Questions How have PIRS shares performed this year? Pieris Pharmaceuticals' stock was trading at $14.56 at the start of the year. Since then, PIRS stock has increased by 17.0% and is now trading at $17.04. View the best growth stocks for 2024 here. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($2.76) EPS for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative trailing twelve-month return on equity of 101.29%. When did Pieris Pharmaceuticals' stock split? Pieris Pharmaceuticals shares reverse split on the morning of Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' top institutional investors include Lynx1 Capital Management LP (3.30%), Renaissance Technologies LLC (0.87%) and Acadian Asset Management LLC (0.82%). Insiders that own company stock include Adar1 Capital Management, Llc, Christopher P Kiritsy and Tim Demuth. View institutional ownership trends. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN) and Dynavax Technologies (DVAX). This page (NASDAQ:PIRS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PIRS Stock Alerts